Jérôme Bédier, CEO ofOlon France, talks about the impact of the Eurobiomed network in developing collaborations between healthcare innovation players in the South of France.
What are the new prospects for Olon France, formerly GTP Bioways, since its integration into the Olon Group?
Since July 2024, GTP Bioways has taken on a new dimension by joining the Olon group, a major industrial player with around 3,000 employees. This integration enables us to offer a complete range of bioproduction services, particularly for monoclonal antibodies and ADCs (Antibody-Drug Conjugates).
Our various sites in France - Labège, Toulouse, Saint-Julien-en-Genevois and Veyron-Monton - are now part of an international dynamic with significant development prospects, such as the increase in our coupling capacity from 100 to 500 liters. The Group also offers us a considerable change of scale, particularly in microbial processes, where production capacities are multiplied by 1000.
How does belonging to the Eurobiomed community contribute to the development of your business?
The strength of the Eurobiomed network has enabled us to forge collaborations with several member companies. One public example is our partnership with Abionyx in the Toulouse region. In all, five projects have been initiated with cluster members, in both process development and GMP production.
How is Eurobiomed's location an asset for Olon France?
Eurobiomed's presence on the Mediterranean arc, from Nice to Toulouse, via Marseille and Montpellier, fits perfectly with our territorial network. This proximity facilitates exchanges and the development of collaborative projects. The events organized by the cluster and our membership of this shared network create a favorable environment for interaction between the various players involved in healthcare innovation. This territorial dimension is a real catalyst for the development of our activities.
